SCHEMBL14095960

SCHEMBL14095960

Cc1ccccc1C(=O)Nc1cccc(NC(=S)NC(=O)c2cccc(Cl)c2)c1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.69
SMN1; SMN2 Q16637 3/20 0.69
NPC1 O15118 2/20 0.69
RAB9A P51151 2/20 0.69
HPGD P15428 1/20 0.69
KMT2A Q03164 3/20 0.67
MAPT P10636 3/20 0.67
MEN1 O00255 2/20 0.67
HTT P42858 1/20 0.67
POLB P06746 1/20 0.65
CYP1A2 P05177 1/20 0.63
CYP3A4 P08684 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
KCNK3 O14649 2/20 0.62
KCNK9 Q9NPC2 2/20 0.62
L3MBTL1 Q9Y468 1/20 0.61
LMNA P02545 1/20 0.61
ALOX12 P18054 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3046207 0.84 SMN1; SMN2 (0.84) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL3049631 0.83 SMN1; SMN2 (0.79) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL3049551 0.83 NPC1 (0.78) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL12225785 0.83 FADS1 (0.70) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL3048128 0.80 NPC1 (0.73) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL3049979 0.79 SMN1; SMN2 (0.90) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL19337844 0.79 SMO (0.79) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL11668137 0.78 KCNK3 (0.84) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL3054545 0.78 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL3051204 0.78 NPC1 (0.74) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv ACHILLION PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv ACHILLION PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv RNASE1, SARS1, EIF2AK2 ALDH1A1 2930/4885SMN1; SMN2 4344/4885NPC1 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.